Home > Resources > Whitepapers > Artificial Intelligence's Potential Role in the Revolution of Drug Discovery

Artificial Intelligence's Potential Role in the Revolution of Drug Discovery

September 10, 2019

Modern drug discovery is a complicated process that requires identification of disease targets, bioactive substances that act upon those targets, and finally optimization of those drug candidates.

Spotlight

Obagi Medical Products

Obagi Medical Products, Inc., a division of Valeant Pharmaceuticals North America, is a specialty pharmaceutical company that develops, markets and sells, and is the leading provider of proprietary topical aesthetic and therapeutic clinically-proven skin care systems in the physician-dispense market. The systems are designed to prevent and improve the most common and visible skin disorders. The foundation of the company began in 1988 with the creation of the Obagi Nu-Derm® System, developed by leading skin care experts. In 1997 the company officially began operations as Obagi Medical Products, Inc.

OTHER WHITEPAPERS

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

Read More

Employing Singleuse Technology to Control Frozen Bulk Drug Storage

whitePaper | September 29, 2022

New biopharmaceutical drug products that alter and even save lives can be very profitable for their developers.

Read More

Helping Patients Find and Engage with Clinical Trials

whitePaper | June 16, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible

Read More

Best Practices for RIM Business Process Automation

whitePaper | December 29, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

Read More

Global Use of Medicines 2023

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

Read More

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.

Read More

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

Read More

Employing Singleuse Technology to Control Frozen Bulk Drug Storage

whitePaper | September 29, 2022

New biopharmaceutical drug products that alter and even save lives can be very profitable for their developers.

Read More

Helping Patients Find and Engage with Clinical Trials

whitePaper | June 16, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible

Read More

Best Practices for RIM Business Process Automation

whitePaper | December 29, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

Read More

Global Use of Medicines 2023

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

Read More

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of
any company. For those in pharmaceutical contract research, development, or manufacturing.

Read More

More Whitepapers

Spotlight

Obagi Medical Products

Obagi Medical Products, Inc., a division of Valeant Pharmaceuticals North America, is a specialty pharmaceutical company that develops, markets and sells, and is the leading provider of proprietary topical aesthetic and therapeutic clinically-proven skin care systems in the physician-dispense market. The systems are designed to prevent and improve the most common and visible skin disorders. The foundation of the company began in 1988 with the creation of the Obagi Nu-Derm® System, developed by leading skin care experts. In 1997 the company officially began operations as Obagi Medical Products, Inc.

Events